An Oral Galectin Inhibitor in COVID-19-A Phase II Randomized Controlled Trial.

Alben SigamaniKevin H MayoMichelle C MillerHana Chen-WaldenSurendar ReddyDavid Platt

Published in: Vaccines (2023)

PL-M is safe and effective for clinical use in reducing viral loads and promoting rapid viral clearance in COVID-19 patients by inhibiting SARS-CoV-2 entry into cells through the inhibition of Gal-3.

Keyphrases

sars cov
phase ii
randomized controlled trial
clinical trial
open label
induced apoptosis
respiratory syndrome coronavirus
study protocol
signaling pathway
cell cycle arrest
phase iii
double blind
oxidative stress
cell proliferation
quantum dots